Experimental drug looks to be gastric bypass surgery in pill form
SMRTR summary
Syntis Bio's new drug demonstrated 1% weekly weight loss in rats over six weeks without muscle loss, and a small human study found it safe with potential metabolic benefits, showing promise for effective weight management.
SMRTR provides this summary for quick context. The original article belongs to Ars Technica.
Read the original article